CAR.CD19 NK cells

N/A

Report date: 2025/03/14 16:54:56

Base Information

Drug NameCAR.CD19 NK cells
Drug Alias Nameanti-CD19 CAR NK-cell therapy (Sandhill therapeutics/Ospedale Pediatrico Bambino Gesu/Universita degli Studi di Napoli Federico II/Universita Degli Studi di Genova/Istituto G Gaslini/Sapienza University of Rome)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSandhill Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSandhill Therapeutics IncUniversity of Naples Federico IIOspedale Pediatrico Bambino Gesu +[6] 
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A